These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2053469)

  • 1. Covalent inhibitors of the gelation of sickle cell hemoglobin and their effects on function.
    Manning JM
    Adv Enzymol Relat Areas Mol Biol; 1991; 64():55-91. PubMed ID: 2053469
    [No Abstract]   [Full Text] [Related]  

  • 2. The mechanism of action of two anti-sickling agents: sodium cyanate and glyceraldehyde.
    Manning JM; Acharya AS
    Am J Pediatr Hematol Oncol; 1984; 6(1):51-4. PubMed ID: 6711764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitors of sickling.
    Mentzer WC
    Am J Pediatr Hematol Oncol; 1982; 4(3):320-7. PubMed ID: 7149171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiologic and rheologic effects of the antisickling agent ethacrynic acid and its N-butylated derivative on normal and sickle erythrocytes.
    Orringer EP; Blythe DS; Whitney JA; Brockenbrough S; Abraham DJ
    Am J Hematol; 1992 Jan; 39(1):39-44. PubMed ID: 1536139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a novel class of covalent modifiers of hemoglobin as potential antisickling agents.
    Omar AM; Mahran MA; Ghatge MS; Chowdhury N; Bamane FH; El-Araby ME; Abdulmalik O; Safo MK
    Org Biomol Chem; 2015 Jun; 13(22):6353-70. PubMed ID: 25974708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetic assay shows that increasing red cell volume could be a treatment for sickle cell disease.
    Li Q; Henry ER; Hofrichter J; Smith JF; Cellmer T; Dunkelberger EB; Metaferia BB; Jones-Straehle S; Boutom S; Christoph GW; Wakefield TH; Link ME; Staton D; Vass ER; Miller JL; Hsieh MM; Tisdale JF; Eaton WA
    Proc Natl Acad Sci U S A; 2017 Jan; 114(5):E689-E696. PubMed ID: 28096387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in the understanding of sickle cell anemia.
    Charache S
    Hosp Pract (Off Ed); 1986 Feb; 21(2):173-8, 182-90. PubMed ID: 2419352
    [No Abstract]   [Full Text] [Related]  

  • 8. Time resolved absorption study of the reaction of hydroxyurea with sickle cell hemoglobin.
    Kim-Shapiro DB; King SB; Bonifant CL; Kolibash CP; Ballas SK
    Biochim Biophys Acta; 1998 Mar; 1380(1):64-74. PubMed ID: 9545536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of methyl acetyl phosphate, a covalent antisickling agent, on the density profiles of sickle erythrocytes.
    Ueno H; Yatco E; Benjamin LJ; Manning JM
    J Lab Clin Med; 1992 Jul; 120(1):152-8. PubMed ID: 1613320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A view of the current status of antisickling therapy.
    Brewer GJ
    Am J Hematol; 1976; 1(1):121-8. PubMed ID: 790948
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of citrate agar electrophoresis in evaluation of antisickling agents.
    Wilson E; Winter WP
    J Natl Med Assoc; 1981 Feb; 73(2):111-6. PubMed ID: 7205973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The molecular basis of antisickling agents.
    Franklin IM; Huehns ER
    Trans R Soc Trop Med Hyg; 1980; 74(6):695-700. PubMed ID: 7210123
    [No Abstract]   [Full Text] [Related]  

  • 13. Targeting βCys93 in hemoglobin S with an antisickling agent possessing dual allosteric and antioxidant effects.
    Kassa T; Strader MB; Nakagawa A; Zapol WM; Alayash AI
    Metallomics; 2017 Sep; 9(9):1260-1270. PubMed ID: 28770911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of cetiedil on erythrocyte sickling: new type of antisickling agent that may affect erythrocyte membranes.
    Asakura T; Ohnishi ST; Adachi K; Ozguc M; Hashimoto K; Singer M; Russell MO; Schwartz E
    Proc Natl Acad Sci U S A; 1980 May; 77(5):2955-9. PubMed ID: 6930678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of methyl isocyanate (MIC) on rat erythrocytes.
    Agrawal D; Gupta GS; Shukla JS; Dutta KK; Ray PK
    Arch Toxicol; 1990; 64(4):332-5. PubMed ID: 2143649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of 3 varieties of antisickling substances measured by ektacytometry as a function of oxygen pressure].
    Feo CJ; Johnson RM; Nossal M
    C R Seances Acad Sci III; 1983; 296(19):911-6. PubMed ID: 6412992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sickle-cell anemia: molecular and cellular bases of therapeutic approaches (third of three parts).
    Dean J; Schechter AN
    N Engl J Med; 1978 Oct; 299(16):863-70. PubMed ID: 692579
    [No Abstract]   [Full Text] [Related]  

  • 18. Sickle hemoglobin aggregation: a new class of inhibitors.
    Votano JR; Gorecki M; Rich A
    Science; 1977 Jun; 196(4295):1216-9. PubMed ID: 870976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extracorporeal treatment of erythrocytes in sickle cell anemia: hemoglobin carbamylation.
    Diederich D; Curran M; Odenbaugh A; Diederich A; Core E
    Tex Rep Biol Med; 1980-1981; 40():313-22. PubMed ID: 7323976
    [No Abstract]   [Full Text] [Related]  

  • 20. A new antisickling agent: in vitro studies of its effect on S/S erythrocytes and on hemoglobin S.
    Adhikary PK; Haynes JK; Patthey HL; Rhodes RS
    Experientia; 1978 Jun; 34(6):804-6. PubMed ID: 658310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.